Shunmin Huang1,2, Jing Yang1,2, Fangmeng Fu3, Chuan Wang3, Xiaoxiong Guo4, Baochang He5, Danni Xiao6, Hongfu Cai1,2, Maobai Liu1,2. 1. Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, 350001, China. 2. School of Pharmacy, Fujian Medical University, Fuzhou, 350122, China. 3. Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, China. 4. Department of Gastroenterology, Fujian Medical University Union Hospital, Fuzhou, 350001, China. 5. Department of Epidemiology & Biostatistics, School of Public Health, Fujian Medical University, Fuzhou, 350122, China. 6. Department of Ultrasound, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
Abstract
Aim: To screen clinical and genetic risk factors and examine their combined effect on docetaxel, epirubicin and cyclophosphamide (TEC) regimen-induced liver injury (TEC-ILI). Patients & methods: We enrolled 396 breast cancer patients, and TEC-ILI-associated factors were screened by logistic regression analyses. Results: SOD2 rs4880 and ABCG2 rs2231142 polymorphisms correlated with an increased risk of TEC-ILI. Multivariate analysis incorporating clinical and genetic factors revealed that ABCC1 rs246221 (CC) and SOD2 rs4880 (AG/GG) increased the risk of TEC-ILI. Patients with at least two risk factors among nonalcoholic fatty liver disease, high low-density lipoproteinemia levels and the rs246221 or rs4880 adverse genotypes exhibited a significantly increased risk of developing TEC-ILI. Conclusion: The combination of clinical and genetic risk factors had higher predictive value for TEC-ILI than the interclinical risk factors alone.
Aim: To screen clinical and genetic risk factors and examine their combined effect on docetaxel, epirubicin and cyclophosphamide (TEC) regimen-induced liver injury (TEC-ILI). Patients & methods: We enrolled 396 breast cancerpatients, and TEC-ILI-associated factors were screened by logistic regression analyses. Results:SOD2rs4880 and ABCG2rs2231142 polymorphisms correlated with an increased risk of TEC-ILI. Multivariate analysis incorporating clinical and genetic factors revealed that ABCC1rs246221 (CC) and SOD2rs4880 (AG/GG) increased the risk of TEC-ILI. Patients with at least two risk factors among nonalcoholic fatty liver disease, high low-density lipoproteinemia levels and the rs246221 or rs4880 adverse genotypes exhibited a significantly increased risk of developing TEC-ILI. Conclusion: The combination of clinical and genetic risk factors had higher predictive value for TEC-ILI than the interclinical risk factors alone.
Entities:
Keywords:
TEC regimen-induced liver injury; combined analysis; early breast cancer; gene polymorphism; risk factors
Authors: Nicholas R Powell; Tyler Shugg; Reynold C Ly; Costantine Albany; Milan Radovich; Bryan P Schneider; Todd C Skaar Journal: Front Oncol Date: 2022-01-31 Impact factor: 6.244